Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.

Journal of viral hepatitis·2015

Same author

Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.

Journal of viral hepatitis·2013

Same author

Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Digestive diseases and sciences·2012

Same author

Ursodeoxycholic acid in primary sclerosing cholangitis.

Alimentary pharmacology & therapeutics·2012

Same author

Patients with gastroesophageal reflux disease and respiratory manifestations do not present lung function disorders during cardiopulmonary exercise test.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2010

Same author

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study.

Alimentary pharmacology & therapeutics·2009

Search research articles

Related Experiment Video

Updated: May 25, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Meta-analysis: antiviral treatment for hepatitis D.

C Triantos¹, M Kalafateli, V Nikolopoulou

¹Department of Gastroenterology, University Hospital of Patras, Stamatopoulou 4, Patras, Greece. chtriantos@hotmail.com

Alimentary Pharmacology & Therapeutics

|January 26, 2012

Summary

Hepatitis D (HDV) treatment remains challenging. Pegylated interferon alfa (PEG-IFNa) shows superiority over other medications for viral clearance and sustained response, suggesting its potential in future combination therapies.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Experiment Videos

Last Updated: May 25, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Area of Science:

Hepatology
Virology
Clinical Pharmacology

Background:

Hepatitis D virus (HDV) infection lacks effective therapeutic options.
Current treatments for HDV are unsatisfactory, necessitating further research.

Purpose of the Study:

To conduct a meta-analysis evaluating the efficacy of various treatments for Hepatitis D.
To compare different interferon-based therapies for HDV infection.

Main Methods:

Systematic literature search of Medline, Scopus, Cochrane Library, and ISI Web of Knowledge.
Inclusion of randomized clinical trials (RCTs) comparing interferon alfa (IFNa), pegylated interferon alfa (PEG-IFNa), and combination therapies.
Endpoints included biochemical and virological response at end of treatment (EOT) and end of follow-up (EOFUP), histological improvement, and HDAg clearance.

Main Results:

Interferon alfa (IFNa) demonstrated efficacy for end-of-treatment (EOT) biochemical and virological response but not sustained response.
High-dose IFNa was superior to low-dose IFNa for EOT outcomes.
Pegylated interferon alfa (PEG-IFNa) showed significant advantages in EOT virological response, EOFUP virological response, and necroinflammatory activity improvement compared to other medications.

Conclusions:

Long-term suppression of HDV RNA by IFNa is not consistently maintained.
Adding lamivudine to IFNa did not show significant benefits.
PEG-IFNa is a more effective treatment option for HDV infection, outperforming other medications in achieving virological response and sustained viral suppression.